Oral Tirzepatide Class Action Lawsuit- Consumer Safety Alert

Chimicles Schwartz Kriner & Donaldson-Smith LLP has filed a nationwide class action lawsuit involving the marketing and sale of oral tirzepatide tablets on SkinnyRx and related websites. The lawsuit alleges that online telehealth companies and compounding pharmacies deceived consumers by promoting these tablets as safe and effective GLP-1 weight-loss medications, even though no FDA-approved oral tirzepatide exists.

The class action lawsuit names Foothills Professional Pharmacy, Ltd. (Foothills Pharmacy), Avocado Health Technology, Inc., TeleRx Providers, P.C., and others as defendants.

What the Lawsuit Alleges

Tirzepatide is the active ingredient in Mounjaro® and Zepbound®, which are FDA-approved injectable medications. Tirzepatide is a peptide, and there is no clinical evidence establishing that it can produce a therapeutic effect when delivered orally or sublingually.

The lawsuit further alleges that Defendants:

• Marketed unapproved oral tirzepatide tablets and ODT-style dissolving tablets
• Represented these compounded products as legitimate GLP-1 weight-loss medications
• Used telehealth storefronts and shell websites to create the appearance of independent providers
• Issued prescriptions through an automated process with little or no medical review
• Dispensed the tablets through Foothills Professional Pharmacy
• Misled consumers into believing the tablets were safe, effective, FDA-compliant, or equivalent to Mounjaro®, Zepbound®, or Rybelsus®

Consumers have reported that these tablets were ineffective, unsafe, improperly compounded, or distributed without any genuine medical evaluation.

Who May Be Affected

You may be part of the proposed class if you purchased oral tirzepatide, oral GLP-1 capsules, tirzepatide ODT tablets, or any similar compounded GLP-1 product from online brands or telehealth websites, including but not limited to:

• SkinnyRx

• Thinly

• Sprout (Sprout Health)

• Oana (Oana Health)

This includes any telehealth website or online clinic that sold “oral tirzepatide” and fulfilled orders through Foothills Professional Pharmacy.

Potential Indicators That You May Have Been Misled

Consumers have reported experiences such as:

• Being told that “oral tirzepatide works like Rybelsus,” “oral Mounjaro,” “oral Zepbound,” “Mounjaro pill,” or “Zepbound pill.”
• Receiving tablets dispensed by Foothills Professional Pharmacy
• Being prescribed the medication without ever speaking to a licensed clinician
• Experiencing no weight-loss effects

If you experienced any of these issues, you may be eligible to participate in the lawsuit.

If You Purchased Oral Tirzepatide, We Want to Hear from You

We want to hear from you if you purchased oral tirzepatide, oral GLP-1/GIP peptides, tirzepatide ODT tablets, or any other compounded oral tirzepatide GLP-1 product from an online telehealth company.